Evaluation of the Feasibility and Safety of Ifosfamide-Based Chemotherapy Regimens for Sarcomas in the Outpatient Setting.

Authors

Mina Seo, Firas Hatoum, Jennifer Swank, Leidy Isenalumhe, Allison Koblitz, Andrele Pena, Donn Davis, Jeffrey Woerz, Syeda Saba Kareem, Heather Buffington, Andrew S Brohl, Jonathan Metts, Mihaela Druta, Amy Schneider, Jad Chahoud

Published in

JCO oncology practice. Pages OP2501196. Jul 06, 2026. Epub Jul 06, 2026.

Abstract

Ifosfamide is traditionally administered in an inpatient setting because of risks of neurotoxicity and hemorrhagic cystitis. To optimize quality of life while tackling the rising cancer care costs, organizations have been shifting chemotherapy administration to outpatient settings. This single-center, retrospective cohort study evaluated the safety and feasibility of administering ifosfamide-based chemotherapy regimens, MAI (mesna, doxorubicin, ifosfamide) and IE (ifosfamide, etoposide), in an outpatient service at a National Cancer Institute-designated Comprehensive Cancer Center.
This single-center study included patients age 18-60 years treated between 2018 and 2024. Fifty-eight patients receiving MAI or IE were managed either through the outpatient service or in the inpatient setting. Clinical outcomes, including readmissions, urgent care visits, toxicities, and treatment completion, were compared. Hospital resource utilization was assessed by estimating average inpatient bed days saved.
The outpatient service saved an estimated 16.2 bed days per patient and 3.7 bed days per cycle. Clinical outcomes were comparable, with similar readmission (18.1% v 19.2%) and urgent care visit rates (5.5% v 4.8%), and no cases of hemorrhagic cystitis were reported. Grade ≥3 hematologic toxicities and treatment completion rates (>90%) were also similar across both arms.
These findings demonstrate that ifosfamide-based regimens through a structured outpatient model are both safe and reducing hospital resource utilization while maintaining treatment adherence and patient safety.

PMID:
42407003
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.